2,457 material Form 8-K filings that 2,074 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
PDS Biotechnology said NantWorks exercised outstanding common stock warrants at $0.22 per share, for 17,699,115 shares or pre-funded warrants in lieu of shares, bringing about $3.9 million in gross proceeds to the company. The warrants came from a September 2026 private placement that raised about $11.3 million gross, and the company plans to use the proceeds to support its lead program and general corporate purposes.
NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, about $3.9 million in gross proceeds.
Warrants were issued in the private placement that initially closed on September 14, 2026, which raised about $11.3 million gross.
Exercise above the 19.9% beneficial ownership limit was taken as pre-funded warrants at $0.00033 per share, which do not expire.
Proceeds, with September 2026 placement net proceeds, will support PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, the PDS0101 partnership strategy and general corporate purposes.
America's Car-Mart amended its credit agreement with Silver Point Finance and lenders to waive certain anticipated or existing events of default through September 7, 2026, and has since extended that date and related relief repeatedly. On November 9, 2026, the agent and lenders agreed to extend the Scheduled Termination Date and temporary relief on minimum liquidity and Collateral Coverage Ratio requirements through November 12, 2026, which signals the company is operating under short-term lender forbearance.
Credit Agreement dated October 30, 2025, amended by First Amendment and Limited Waiver with Silver Point Finance, LLC as Agent
Scheduled Termination Date extended from September 7, 2026 to November 9, 2026 and then to November 12, 2026
Temporary relief on minimum liquidity thresholds and minimum Collateral Coverage Ratio extended through November 12, 2026
On November 5, 2026, Codexis and its subsidiary entered a Loan and Security Agreement with Trinity Capital Inc. as agent, providing up to $60.0 million in term loans, of which $42.5 million was funded at closing. The company used that loan and cash on hand to repay its Innovatus loan in full, and issued lender warrants for up to 1,666,668 shares of common stock, which would increase the share count if exercised.
Tranche A term loan of $42.5 million funded November 5, 2026; up to $60.0 million available in total across three tranches
Interest at the greater of 10.50% or a variable rate tied to prime plus 3.75%; interest-only until November 1, 2030; maturity November 1, 2031
Repaid the Innovatus Loan Agreement in full for an aggregate of approximately $43.6 million
Lender warrants for up to 1,666,668 shares at $1.08 per share, expiring November 5, 2036; loans secured by substantially all assets
Scholar Rock agreed on November 9, 2026, to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech US Inc. for $205 million in cash, payable at closing, which remains subject to customary conditions including the Hart-Scott-Rodino waiting period. The same day it reported third-quarter results, with its first ISEMBYLD product revenue of $0.6 million offset by a wider net loss of $107.2 million.
Buyer BioNTech US Inc. agreed to pay $205 million in cash at closing for the voucher, awarded after the September 11, 2026 FDA approval of ISEMBYLD
Q3 2026 net product revenue was $0.6 million, versus none in Q3 2025
Q3 2026 net loss was $107.2 million, or $0.81 per share, compared with a net loss of $102.2 million, or $0.90 per share, a year earlier
Cash, cash equivalents and marketable securities were $413.6 million as of September 30, 2026
WhiteFiber's indirect subsidiaries entered into a $300.0 million Term Loan Credit Agreement with Morgan Stanley Senior Funding and a lender group on November 9, 2026. No loans had been funded as of the filing date, and initial funding depends on conditions tied to the first 40 megawatts of the NC-1 data center in Madison, North Carolina. The loans are not guaranteed by WhiteFiber, Inc., but the financing adds debt tied to the project and includes covenants and a mortgage on the data center.
Facilities: $200.0 million initial term loan and $100.0 million delayed-draw term loan, both maturing on the fifth anniversary of initial funding
Interest at Term SOFR (2.00% floor) plus 6.00%, or base rate (3.00% floor) plus 5.00%, at the borrower's election
No loans funded as of the filing; initial funding is scheduled within 30 days after closing, with up to two 30-day extensions
Loans are not guaranteed by WhiteFiber, Inc.; the Operating Partnership must deliver an unsecured Phase 1 completion guarantee before initial funding
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.